Krystal Biotech Stock
Price
Target price
€122.55
€122.55
-1.380%
-1.7
-1.380%
€204.88
12.09.25 / Tradegate
WKN: A2JH2F / Symbol: KRYS / Name: Krystal Biotech / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Krystal Biotech Stock
A loss of -1.380% shows a downward development for Krystal Biotech.
Krystal Biotech is currently one of the favorites of our community with 20 Buy predictions and no Sell predictions.
With a target price of 204 € there is a hugely positive potential of 66.46% for Krystal Biotech compared to the current price of 122.55 €.
So far the community has only identified positive things for Krystal Biotech stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Krystal Biotech in the next few years
Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Krystal Biotech vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Krystal Biotech | -1.380% | -4.556% | -0.406% | -32.124% | -19.481% | 71.399% | - |
| Ardelyx Inc. | -0.770% | 1.041% | 17.421% | 0.071% | 13.353% | 326.428% | 14.274% |
| Evolus Inc | -1.600% | -3.906% | 28.125% | -54.104% | -41.429% | -41.981% | 109.041% |
| Champions Oncology Inc | -2.730% | -5.310% | -0.926% | 31.127% | 12.395% | -25.694% | -9.322% |
Comments
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $240.00 price target on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its price target lowered by analysts at Chardan Capital from $219.00 to $216.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $219.00 price target on the stock.
Show more
Ratings data for KRYS provided by MarketBeat